Table 5.
ARFL and ARV7 conversion at PD. Percentages refer to the fraction of patients within groups who at baseline shared biomarker constellation (first column). Numbers in brackets refer to the number of patients with specific ARFL/ARV7 profile analyzed at PD.
| Progressive Disease (PD) | |||||
|---|---|---|---|---|---|
| Baseline | ARFL+ ARV7+ |
ARFL+ ARV7− |
ARFL− ARV7+ |
ARFL− ARV7− |
no CTCs |
| ARFL+, ARV7+ (8) | 75% (6) | 12.5% (1) | 0 | 0 | 12.5% (1) |
| ARFL+, ARV7− (9) | 44.4% (4) | 22.2% (2) | 0 | 0 | 33.3% (3) |
| ARFL−, ARV7− (5) | 20% (1) | 20% (1) | 20% (1) | 20% (1) | 20% (1) |
| no CTCs (3) | 0 | 33.3% (1) | 0 | 0 | 66.7% (2) |
| Total (25) | 11 | 5 | 1 | 1 | 7 |